Skip to main content

Table 1 Baseline characteristics

From: The efficacy and safety of tranexamic acid for reducing blood loss following simultaneous bilateral total knee arthroplasty: a multicenter retrospective study

Baseline Characteristic IV group (n = 192) Combined group (n = 135) Control group (n = 248) P
Age (y) 66.2 ± 7.9 65.8 ± 9.1 66.6 ± 9.5 0.675
Gender(M/F) 32/160 23/112 43/205 0.983
BMI (kg/ m2) 27.1 ± 3.8 27.6 ± 3.3 27.0 ± 3.5 0.230
Diagnose (OA/IA) 183/9 126/9 238/10 0.514
 Hypertension 67 (34.9%) 59 (43.7%) 85 (34.3%) 0.154
 Diabetes 20 (10.4%) 17 (12.6%) 21 (8.5%) 0.433
Preoperative Hb (g/L) 140.8 ± 12.2 143.2 ± 10.8 141.4 ± 10.4 0.432
 Preoperative Hct 0.415 ± 0.035 0.420 ± 0.032 0.415 ± 0.037 0.758
 PBV (mL) 4047.3 ± 505.6 4060.4 ± 559.1 4020.3 ± 532.1 0.749
Anticoagulation methods     0.398
 LMWH 109 86 153  
 Rivaroxaban 83 49 95  
Anesthesia method     0.578
 General 152 112 195  
 Regional 40 23 53  
ASA class     0.852
 1–2 188 131 241  
 ≥3 4 4 7  
Operating time (min) 120.3 ± 37.1 153.8 ± 43.9 139.3 ± 39.1 < 0.001*
  1. BMI Body mass index = Weight/ Height2, OA Osteoarthritis, IA Inflammatory arthritis, Hb Hemoglobin, Hct Hematocrit, PBV patient blood volume, LMWH low-molecular-weight heparin, ASA American Society of Anesthesiologists
  2. *Significant difference
\